reported significantly lower seroconversion in patients with hematologic malignancies (82%), patients who received anti-CD-20 antibody therapy (59%), and patents who received stem cell transplant (60%); yet, SARS-Cov-2 IgG antibodies developed in patients who received immunotherapy, including those who received anti-PD-1/PD-L1 monoclonal antibodies (100% seroconversion) (25). This evidence concerns the gene CD274 and hematologic disorder.